Latest & greatest articles for aspirin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on aspirin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on aspirin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Aspirin

Acetylsalicylic acid (ASA) more commonly known as aspirin is a painkiller that has a wide range of uses. It is frequently used to treat fever, mild pain, tooth aches, headaches and muscle aches. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) and can be used in the management of conditions such as heart attack, arthritis, blood clots and stroke. Aspirin, has been used for thousands of years, initially extracted from the leaves of willow trees.

Aspirin works in much the same way as other NSAIDs but has additional properties, such as antiplatelet activity which can make it additionally useful. More recently aspirin has been linked with cancer prevention. But the potential benefits of aspirin need to be weighed against the potential side effects, which includes gastrointestinal bleeding and Reye’s syndrome. It should be noted that aspirin should not be used in people who are allergic to drugs such as ibuprofen or a more generalized intolerance to NSAIDs. It should also be used cautiously in asthmatics and/or those with bronchospasm associated with NSAID use.

Research evidence, clinical trials and guidelines on Aspirin

The Trip Database has an extensive collection of articles on aspirin ranging from clinical trials, systematic reviews, clinical guidelines and case reports. These can be found via searching the site.

Top results for aspirin

141. Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants. Full Text available with Trip Pro

Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants. Use of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with lower risk of colorectal cancer.To identify common genetic markers that may confer differential benefit from aspirin or NSAID chemoprevention, we tested gene × environment interactions between regular use of aspirin and/or NSAIDs and single-nucleotide polymorphisms (SNPs) in relation to risk of colorectal (...) cancer.Case-control study using data from 5 case-control and 5 cohort studies initiated between 1976 and 2003 across the United States, Canada, Australia, and Germany and including colorectal cancer cases (n=8634) and matched controls (n=8553) ascertained between 1976 and 2011. Participants were all of European descent.Genome-wide SNP data and information on regular use of aspirin and/or NSAIDs and other risk factors.Colorectal cancer.Regular use of aspirin and/or NSAIDs was associated with lower risk

2015 JAMA

142. Acetyl Salicylic Acid (ASA)

Acetyl Salicylic Acid (ASA) © 2015 Thrombosis Canada Page 1 of 4 ACETYL SALICYLIC ACID (ASA) OBJECTIVE: To provide information on the use of acetyl salicylic acid in the prevention of vascular thromboembolic events. BACKGROUND: Acetyl salicylic acid (ASA) is well-established in the management of acute myocardial infarction and in the secondary prevention of cardiovascular disease among both men and women, based on large randomized trials. More recently, its role in the prevention of recurrent (...) venous thromboembolism has been demonstrated. The net benefit of ASA use depends on weighing the anticipated reduction in cardiovascular events against the increased risk of gastrointestinal bleeding. MECHANISM OF ACTION OF ASA: ASA irreversibly inhibits platelet aggregation by inhibiting thromboxane A 2 (TxA 2 ) synthesis. INDICATIONS FOR ASA: Antiplatelet therapy is recommended for all patients with the following, unless contraindicated: 1) Cardiac: For all patients with symptomatic coronary artery

2015 Thrombosis Interest Group of Canada

143. Systematic review with meta-analysis: Low-dose aspirin reduces morbidity and mortality in pregnant women at high-risk for preeclampsia

Systematic review with meta-analysis: Low-dose aspirin reduces morbidity and mortality in pregnant women at high-risk for preeclampsia Low-dose aspirin reduces morbidity and mortality in pregnant women at high-risk for preeclampsia | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Low-dose aspirin reduces morbidity and mortality in pregnant women at high-risk for preeclampsia Article Text Midwifery Systematic review with meta-analysis Low-dose

2015 Evidence-Based Nursing

144. Systematic review: Updated review identifies no adverse impact on mother or offspring during the perinatal period of aspirin use for prevention of preeclampsia Full Text available with Trip Pro

Systematic review: Updated review identifies no adverse impact on mother or offspring during the perinatal period of aspirin use for prevention of preeclampsia Updated review identifies no adverse impact on mother or offspring during the perinatal period of aspirin use for prevention of preeclampsia | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more (...) period of aspirin use for prevention of preeclampsia Article Text Therapeutics/Prevention Systematic review Updated review identifies no adverse impact on mother or offspring during the perinatal period of aspirin use for prevention of preeclampsia Free Paul Leeson Statistics from Altmetric.com Commentary on : Henderson JT , Whitlock EP , O'Connor E , et al . Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the US Preventive Services Task

2015 Evidence-Based Medicine

145. 2015 AHA/ASA Focused Update of the 2013 Guidelines for the Early Management of Patients with Acute Ischemic Stroke Regarding Endovascular Treatment

2015 AHA/ASA Focused Update of the 2013 Guidelines for the Early Management of Patients with Acute Ischemic Stroke Regarding Endovascular Treatment 3020 Purpose—The aim of this guideline is to provide a focused update of the current recommendations for the endovascular treatment of acute ischemic stroke. When there is overlap, the recommendations made here supersede those of previous guidelines. Methods—This focused update analyzes results from 8 randomized, clinical trials of endovascular (...) the express permission of the American Heart Association. Instructions for obtaining permission are located at http://www.heart.org/HEARTORG/General/Copyright- Permission-Guidelines_UCM_300404_Article.jsp. A link to the “Copyright Permissions Request Form” appears on the right side of the page. © 2015 American Heart Association, Inc. Stroke is available at http://stroke.ahajournals.org DOI: 10.1161/STR.0000000000000074 AHA/ASA Guideline Downloaded from http://ahajournals.org by on March 27, 2019Powers et

2015 Congress of Neurological Surgeons

146. 2015 aha/asa focused update of the 2013 guidelines for the early management of patients with acute ischemic stroke regarding endovascular treatment Full Text available with Trip Pro

2015 aha/asa focused update of the 2013 guidelines for the early management of patients with acute ischemic stroke regarding endovascular treatment 2015 American Heart Association/American Stroke Association Focused Update of the 2013 Guidelines for the Early Management of Patients With Acute Ischemic Stroke Regarding Endovascular Treatment | Stroke Search Hello Guest! Login to your account Email Password Keep me logged in Search April 2019 March 2019 February 2019 February 2019 January 2019

2015 American Academy of Neurology

147. Salicylate-containing rubefacients for acute and chronic musculoskeletal pain in adults. Full Text available with Trip Pro

Salicylate-containing rubefacients for acute and chronic musculoskeletal pain in adults. Rubefacients containing salicylates cause irritation of the skin and are believed to relieve various musculoskeletal pains. They are available on prescription, and are common components in over-the-counter remedies. This is an update of a review of rubefacients for acute and chronic pain, originally published in 2009, which found limited evidence for efficacy.To assess the efficacy and safety of topically (...) applied salicylates in acute and chronic musculoskeletal pain in adults.We searched CENTRAL, MEDLINE, and EMBASE, from inception to 22 August 2014, together with the Oxford Pain Relief Database, two clinical trial registries, and the reference lists of included studies and relevant reviews.Randomised, double-blind, placebo- or active-controlled clinical trials of topical rubefacients containing salicylates to treat musculoskeletal pain in adults, with at least 10 participants per treatment arm

2014 Cochrane

148. Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Japanese Patients 60 Years or Older With Atherosclerotic Risk Factors: A Randomized Clinical Trial. Full Text available with Trip Pro

Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Japanese Patients 60 Years or Older With Atherosclerotic Risk Factors: A Randomized Clinical Trial. Prevention of atherosclerotic cardiovascular diseases is an important public health priority in Japan due to an aging population.To determine whether daily, low-dose aspirin reduces the incidence of cardiovascular events in older Japanese patients with multiple atherosclerotic risk factors.The Japanese Primary Prevention Project (...) aspirin 100 mg/d or no aspirin in addition to ongoing medications.Composite primary outcome was death from cardiovascular causes (myocardial infarction, stroke, and other cardiovascular causes), nonfatal stroke (ischemic or hemorrhagic, including undefined cerebrovascular events), and nonfatal myocardial infarction. Secondary outcomes included individual end points.The study was terminated early by the data monitoring committee after a median follow-up of 5.02 years (interquartile range, 4.55-5.33

2014 JAMA Controlled trial quality: predicted high

149. Perioperative Aspirin and Clonidine and Risk of Acute Kidney Injury: A Randomized Clinical Trial. Full Text available with Trip Pro

Perioperative Aspirin and Clonidine and Risk of Acute Kidney Injury: A Randomized Clinical Trial. Acute kidney injury, a common complication of surgery, is associated with poor outcomes and high health care costs. Some studies suggest aspirin or clonidine administered during the perioperative period reduces the risk of acute kidney injury; however, these effects are uncertain and each intervention has the potential for harm.To determine whether aspirin compared with placebo, and clonidine (...) compared with placebo, alters the risk of perioperative acute kidney injury.A 2 × 2 factorial randomized, blinded, clinical trial of 6905 patients undergoing noncardiac surgery from 88 centers in 22 countries with consecutive patients enrolled between January 2011 and December 2013.Patients were assigned to take aspirin (200 mg) or placebo 2 to 4 hours before surgery and then aspirin (100 mg) or placebo daily up to 30 days after surgery, and were assigned to take oral clonidine (0.2 mg) or placebo 2

2014 JAMA Controlled trial quality: predicted high

150. Low-Dose Aspirin Use for the Prevention of Morbidity and Mortality From Preeclampsia: U.S. Preventive Services Task Force Recommendation Statement. Full Text available with Trip Pro

Low-Dose Aspirin Use for the Prevention of Morbidity and Mortality From Preeclampsia: U.S. Preventive Services Task Force Recommendation Statement. Update of the 1996 U.S. Preventive Services Task Force (USPSTF) recommendation on aspirin prophylaxis in pregnancy.The USPSTF reviewed the evidence on the effectiveness of low-dose aspirin in preventing preeclampsia in women at increased risk and in decreasing adverse maternal and perinatal health outcomes, and assessed the maternal and fetal harms (...) of low-dose aspirin during pregnancy.This recommendation applies to asymptomatic pregnant women who are at increased risk for preeclampsia and who have no prior adverse effects with or contraindications to low-dose aspirin.The USPSTF recommends the use of low-dose aspirin (81 mg/d) as preventive medication after 12 weeks of gestation in women who are at high risk for preeclampsia. (B recommendation).

2014 Annals of Internal Medicine

151. Aspirin as adjunctive treatment for giant cell arteritis. (Abstract)

Aspirin as adjunctive treatment for giant cell arteritis. Giant cell arteritis (GCA) is a common inflammatory condition that affects medium and large-sized arteries and can cause sudden, permanent blindness. At present there is no alternative to early treatment with high-dose corticosteroids as the recommended standard management. Corticosteroid-induced side effects can develop and further disease-related ischaemic complications can still occur. Alternative and adjunctive therapies are sought (...) . Aspirin has been shown to have effects on the immune-mediated inflammation in GCA, hence it may reduce damage caused in the arterial wall.To assess the safety and effectiveness of low-dose aspirin, as an adjunctive, in the treatment of giant cell arteritis (GCA).We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (2013, Issue 12), Ovid MEDLINE, Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to January 2014

2014 Cochrane

152. Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia. Full Text available with Trip Pro

Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia. Since hypercoagulability might result in recurrent miscarriage, anticoagulant agents could potentially increase the chance of live birth in subsequent pregnancies in women with unexplained recurrent miscarriage, with or without inherited thrombophilia.To evaluate the efficacy and safety of anticoagulant agents, such as aspirin and heparin, in women with a history of at least two (...) unexplained miscarriages with or without inherited thrombophilia.We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (1 October 2013) and scanned bibliographies of all located articles for any unidentified articles.Randomised and quasi-randomised controlled trials that assessed the effect of anticoagulant treatment on live birth in women with a history of at least two unexplained miscarriages with or without inherited thrombophilia were eligible. Interventions included aspirin

2014 Cochrane

153. Aspirin for VTE prophylaxis in hip and knee replacement surgery

Aspirin for VTE prophylaxis in hip and knee replacement surgery Aspirin for VTE prophylaxis in hip and knee replacement surgery Aspirin for VTE prophylaxis in hip and knee replacement surgery Mitchell MD, Williams K Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Mitchell MD, Williams K. Aspirin for VTE prophylaxis in hip and knee replacement surgery (...) . Philadelphia: Center for Evidence-based Practice (CEP). 2014 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirins; Venous Thromboembolism Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence Center for Evidence-based Practice, University of Pennsylvania Health System, 3535 Market St. Suite 50, Philadelphia PA 19104

2014 Health Technology Assessment (HTA) Database.

154. Low-dose aspirin for the prevention of morbidity and mortality from pre-eclampsia: a systematic evidence review for the U.S. preventive services task force

Low-dose aspirin for the prevention of morbidity and mortality from pre-eclampsia: a systematic evidence review for the U.S. preventive services task force Low-dose aspirin for the prevention of morbidity and mortality from pre-eclampsia: a systematic evidence review for the U.S. preventive services task force Low-dose aspirin for the prevention of morbidity and mortality from pre-eclampsia: a systematic evidence review for the U.S. preventive services task force Henderson JT, Whitlock EP (...) , O'Connor E, Senger CA, Thompson JH, Rowland MG Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Henderson JT, Whitlock EP, O'Connor E, Senger CA, Thompson JH, Rowland MG. Low-dose aspirin for the prevention of morbidity and mortality from pre-eclampsia: a systematic evidence review for the U.S. preventive services task force. Rockville: Agency

2014 Health Technology Assessment (HTA) Database.

155. Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force. (Abstract)

Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force. Preeclampsia is a leading cause of maternal and perinatal morbidity and mortality.To systematically review benefits and harms of low-dose aspirin for preventing morbidity and mortality from preeclampsia.MEDLINE, Database of Abstracts of Reviews of Effects, PubMed, and Cochrane Central Register of Controlled Trials (January 2006 to June 2013 (...) , in addition to 6 RCTs and 2 observational studies of average-risk women to assess harms (7 good-quality). Depending on baseline risk, aspirin use was associated with absolute risk reductions of 2% to 5% for preeclampsia (relative risk [RR], 0.76 [95% CI, 0.62 to 0.95]), 1% to 5% for intrauterine growth restriction (RR, 0.80 [CI, 0.65 to 0.99]), and 2% to 4% for preterm birth (RR, 0.86 [CI, 0.76 to 0.98]). No significant perinatal or maternal harms were identified, but rare harms could not be ruled out

2014 Annals of Internal Medicine

156. Aspirin versus vitamin K antagonist treatment guided by transoesophageal echocardiography in patients with atrial fibrillation: a pilot study (Abstract)

Aspirin versus vitamin K antagonist treatment guided by transoesophageal echocardiography in patients with atrial fibrillation: a pilot study Current stroke risk schemes need improvement of predictive value in patients with atrial fibrillation. Transoesophageal echocardiography (TEE) may facilitate stroke risk assessment in such patients and guide antithrombotic treatment.We randomised 238 patients with non-valvular atrial fibrillation and a moderate stroke risk to aspirin or adjusted vitamin K (...) antagonist therapy after TEE had ruled out thrombogenic features in the atria and aorta. The primary outcome was a composite of stroke, major bleeding, peripheral embolism and all-cause mortality.Mean CHA2DS2-VASc score was 2.1±1.1. The incidences of the composite primary outcome at a mean follow-up of 1.6 years were 3.2% (2.02% per year) in the aspirin group compared to 6.1% (3.84% per year) in the vitamin K antagonists group with an absolute advantage of 2.9 percentage points. Aspirin was non-inferior

2014 EvidenceUpdates Controlled trial quality: uncertain

157. Codeine and acetylsalicylic acid for the management of post-tonsillectomy or adenoidectomy pain: a review of the clinical evidence

Codeine and acetylsalicylic acid for the management of post-tonsillectomy or adenoidectomy pain: a review of the clinical evidence Codeine and acetylsalicylic acid for the management of post-tonsillectomy or adenoidectomy pain: a review of the clinical evidence Codeine and acetylsalicylic acid for the management of post-tonsillectomy or adenoidectomy pain: a review of the clinical evidence CADTH Record Status This is a bibliographic record of a published health technology assessment from (...) a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Codeine and acetylsalicylic acid for the management of post-tonsillectomy or adenoidectomy pain: a review of the clinical evidence. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary with Critical Appraisal. 2013 Authors' conclusions No relevant literature was identified regarding the risk of bleeding associated with the use of codeine

2014 Health Technology Assessment (HTA) Database.

158. Clopidogrel/Acetylsalicylic acid Teva

concentrations. Elimination of ASA is almost exclusively by hydrolysis to salicylic acid (around 1% of ASA dose is excreted unhydrolyzed by the kidney) and starts already in the gut wall. Elimination of acetylsalicylic acid is a first-order process at concentrations in the range between 100-300 µg/mL with a half-life of around 2- 3 hours. 2.3.2.2. Bioequivalence study 2.3.2.2.1. Methodology – Study design Medicinal product no longer authorised Assessment report EMA/CHMP/333195/2014 Page 22/43 This is an open (...) 2.5. Clinical safety 30 2.6. Pharmacovigilance 33 2.7. Risk Management Plan 34 2.8. Product information 39 3. Benefit-Risk Balance 39 Benefit-risk balance 41 4. Recommendations 42 Medicinal product no longer authorised Assessment report EMA/502333/2014 Page 3/43 List of abbreviations AA Arachidonic acid ACE Angiotensin converting enzyme ACS Acute coronary syndrome ADP Adenosine diphosphate AE Adverse event Al(u) Aluminium ANOVA Analysis of variance ASA Acetylsalicylic acid AUC Area under the curve

2014 European Medicines Agency - EPARs

159. Aspirin overdose

. The incidence and severity of premature closure of the ductus arteriosus appears to be dose-related and increases with advancing gestational age beyond 30 weeks. Early obstetric or fetal medicine input is recommended for cases of aspirin overdose in the third trimester as early delivery or additional monitoring may be indicated. Appropriate maternal treatment of aspirin overdose is important to reduce the risk of salicylate toxicity in both the mother and the fetus. There are no published guidelines (...) Aspirin overdose ASPIRIN OVERDOSE IN PREGNANCY 0344 892 0909 ASPIRIN OVERDOSE IN PREGNANCY (Date of issue: December 2012 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . Summary Low-dose aspirin (75-300mg/day) is used as an antiplatelet medication to reduce the risk of thrombosis in cerebrovascular

2014 UK Teratology Information Service

160. Aspirin

Aspirin USE OF ASPIRIN IN PREGNANCY 0344 892 0909 USE OF ASPIRIN IN PREGNANCY (Date of issue: July 2014 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Low-dose aspirin (75-300mg/day) is used as an antiplatelet medication (...) in the prophylaxis of thromboembolic cerebrovascular disease, myocardial infarction and pre-eclampsia. Higher doses of aspirin (up to 4g/day) are used in the control of mild to moderate pain and pyrexia. There is a large body of evidence that shows no association between the use of low-dose aspirin (LDA) during pregnancy and increased risk of spontaneous abortion or stillbirth. Fewer data are available regarding aspirin use at analgesic doses, but again no association with these two outcomes has been reported

2014 UK Teratology Information Service